DaVita Clinical Research - The Place for Health Economics and Outcomes Research

MINNEAPOLIS, May 12, 2011 (BUSINESS WIRE) -- <u>DaVita Clinical Research</u>® (DCR®), a provider of clinical research services focused on kidney care as well as a multitude of specialty therapeutic populations, is setting new standards for its Health Economics and Outcomes Research services. These services, a key focus for DCR, will be on display at the <u>International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting</u> in Baltimore, May 21-25, 2011.

The DCR Health Economics and Outcomes Research team designs and executes studies and economic models and translates the results into tools and products for its customers. By understanding client needs and current trends in the marketplace, DCR has successfully supported access and utilization of multibillion-dollar drug franchises.

DCR's Health Economics and Outcomes Research services include:

- Strategic consulting
- Economic modeling
- Epidemiology and biostatistics
- · Prospective study design, execution, and analysis
- Disease management design, execution, and evaluation
- Psychometric development and validation
- · Commercial reimbursement and formulary placement
- Policy analytics and legislative briefings

"Our global experts come from leadership positions at major pharmaceutical and biotechnology organizations," stated DCR Senior Director, Health Economics and Informatics, <u>Tracy Mayne</u>, Ph.D. "Many Health Economics organizations can execute a study and write publications, but the experts at DCR have first-hand experience in translating the results into strategies and products, providing our clients with the insight to help their customers and grow their businesses."

DCR brings unsurpassed knowledge, skill and expertise to pharmaceutical research, facilitating the success of clinical trials. During ISPOR, at DCR's booth #70, donations will be made on behalf of tradeshow attendees to the National Kidney Foundation to help prevent kidney disease. Additionally, DCR representatives will give an oral presentation on the "Impact of a Pharmacy Refill Management System on Outcomes in ESRD Patients," as well as have two scientific poster presentations at ISPOR.

Podium Session 1: Effects of Drug Management Programs on Patients (DM1)

Title: Impact of a Pharmacy Refill Management System on Outcomes in ESRD Patients

Date: Monday, May 23, 2011 **Time:** 1:45 p.m. - 2:45 p.m.

Poster 1 Title: (PUK1) Incidence and 30-day Mortality of Community Acquired Pneumonia (CAP) in the Medicare Fee-for-Service (FFS)

Population - Poster in collaboration with Pfizer

Date: Monday, May 23, 2011

Poster 2 Title: (PUK 24) Use of Biomarkers in Propensity Score Matching to Mitigate Channeling Bias in a Retrospective Cohort of ESRD

Patients

Date: Monday, May 23, 2011

DaVita Clinical Research and DCR are registered trademarks of <u>DaVita Inc.</u> All other trademarks are the property of their respective owners.

About DaVita Clinical Research

<u>DaVita Clinical Research</u> (DCR) iscommitted to advancing the knowledge and practice of kidney care. DCR brings unsurpassed knowledge, skill, and expertise to pharmaceutical research, facilitating the success of their clients' clinical trials. Its clinical expertise ranges from designing the study to preparing and submitting the final report. DCR's <u>Early Clinical Research</u> unit (Phase I-IIa) and <u>Clinical Development</u> network of physicians and investigative sites is focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas as well as CKD and ESRD populations needed to meet clinical goals. To learn more about DCR, visithttp://www.davitaclinicalresearch.com.

About DaVita

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of March 31, 2011, DaVita operated or provided administrative services at 1,642 dialysis facilities, serving approximately 128,000 patients. DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. The company's leadership development initiatives and corporate social responsibility efforts have been recognized by *Fortune*, *Modern Healthcare*, *Newsweek* and WorldBlu, among others. For more information, please visit http://www.davita.com.

SOURCE: DaVita Clinical Research

DaVita Vince Hancock, 303-405-2272 Vince.hancock@davita.com

https://newsroom.davita.com/press-releases?item=122952